Deadline: 1 July 2024
The Chiesi FAST Discovery Award recognizes the aspiring life-science companies and entrepreneurs who are driving scientific innovation to cure rare disease and developing novel tools and platform technologies for applications in nucleotide therapeutics.
Chiesi Focus Areas
- Chiesi is interested in applications from interested startups developing innovative approaches in the following discovery and early clinical areas of interest:
- In vivo gene editing
- In vivo gene therapy approaches
- Nucleotide delivery technologies
- Chiesi’s target therapeutic areas within rare diseases are:
- Hematology
- Immunology
- Dermatology
- Ophthalmology
- Endo-metabolic
- Inborn errors of metabolism
Disclosure
- The winner of the Chiesi FAST Discovery Award will be fast-tracked into the Fall FAST 2024 program cohort. A dedicated advisor from Chiesi will participate as an advisor to the selected company and participate in the awardees advisory meetings.
Criteria
- Your non-confidential application should highlight your innovative approach to advancing therapies for patients with high unmet needs. All submissions will be reviewed by Chiesi, and one awardee will be selected to receive the Chiesi FAST Discovery Award, a fast-tracked spot in the Fall 2024 FAST California program.
For more information, visit California Life Sciences (CLS).
